Quantum Immunologics, Inc. to Present at Rodman & Renshaw Conference

TAMPA, FL--(Marketwire - September 08, 2009) - Quantum Immunologics, Inc. (QI), a privately owned biotech company announced today that it is scheduled to present at the Rodman & Renshaw 11th Annual Healthcare Conference on Friday, September 11, 2009 at 3:40 p.m. eastern time. Josh Coughlin, QI Board Member and Chief Investment Officer, will provide an overview of QI. The Rodman & Renshaw conference is scheduled to be held at the Palace Hotel in New York City, September 9 - 11, 2009.

About Quantum Immunologics

Quantum Immunologics is dedicated to the research, development and production of products and services that will promote unique, individualized immunologic cancer treatment and early detection technologies with a high rate of efficacy, minimal side effects and greatly reduced cost compared to current treatments.

Quantum Immunologics has received FDA authorization to apply its exclusively licensed patented immunotherapy in a Phase I/II human clinical study. QI's Phase I/II clinical trial, which involves a cohort of 27 patients with advanced-stage metastatic breast cancer, is designed around the use of QI's proprietary dendritic cell therapy, which employs oncofetal antigen ("OFA") to recruit the patient's own immune system to target and combat the cancer cells with the intent to improve patient survivability and quality of life. QI projects the completion of the patient treatment portion of the Phase I/II trial by the end of January 2010.

For more information about QI and its FDA-authorized trials, please visit www.quantumimmunologics.com, or contact Investor Relations at (813) 849-7859.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include, but are not limited to, statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Quantum Immunologics, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.